Neovascular Age-Related Macular Degeneration (nAMD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036
- Published Date : April 7, 2026
- Updated On : July 30, 2026
- Pages : 154
Neovascular Age-Related Macular Degeneration Market Outlook and Forecast
Thelansis’s “Neovascular Age-Related Macular Degeneration (nAMD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Neovascular Age-Related Macular Degeneration treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Neovascular Age-Related Macular Degeneration (nAMD) Overview
Neovascular age-related macular degeneration (nAMD), or wet AMD, is a major cause of vision loss in older adults, driven by abnormal growth and leakage of blood vessels beneath or within the retina. The disease has been transformed by anti-VEGF therapies that suppress the signaling driving this neovascularization, dramatically reducing the severe vision loss that once commonly accompanied nAMD. The persistent challenge is now treatment burden: many patients require repeated intravitreal injections over many years, and real-world outcomes can suffer when treatment schedules are difficult to maintain. Innovation is therefore shifting toward extending treatment durability through longer-acting agents and sustained-release delivery systems, while more ambitious gene therapies aim to enable the eye to continuously produce anti-VEGF proteins after a single administration. Several programs have reported encouraging sustained biological activity and durability signals, although long-term clinical benefit remains under evaluation. For stakeholders, nAMD illustrates how a mature therapeutic category can shift from solving efficacy to solving the burden of chronic treatment.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
Deliverables format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market forecast (2026–2036)
- Bottom-up patient-based market forecasts validated through the top-down sales methodology
- Covers clinically and commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and patient share?
- Which events will have the greatest impact on the market’s trajectory?
- What insights do interviewed experts provide on current and emerging treatments?
- Which pipeline products show the most promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for target profiles?
- What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
- and more…
Neovascular Age-Related Macular Degeneration Market Outlook and Forecast
Thelansis’s “Neovascular Age-Related Macular Degeneration (nAMD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Neovascular Age-Related Macular Degeneration treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Neovascular Age-Related Macular Degeneration (nAMD) Overview
Neovascular age-related macular degeneration (nAMD), or wet AMD, is a major cause of vision loss in older adults, driven by abnormal growth and leakage of blood vessels beneath or within the retina. The disease has been transformed by anti-VEGF therapies that suppress the signaling driving this neovascularization, dramatically reducing the severe vision loss that once commonly accompanied nAMD. The persistent challenge is now treatment burden: many patients require repeated intravitreal injections over many years, and real-world outcomes can suffer when treatment schedules are difficult to maintain. Innovation is therefore shifting toward extending treatment durability through longer-acting agents and sustained-release delivery systems, while more ambitious gene therapies aim to enable the eye to continuously produce anti-VEGF proteins after a single administration. Several programs have reported encouraging sustained biological activity and durability signals, although long-term clinical benefit remains under evaluation. For stakeholders, nAMD illustrates how a mature therapeutic category can shift from solving efficacy to solving the burden of chronic treatment.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
Deliverables format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market forecast (2026–2036)
- Bottom-up patient-based market forecasts validated through the top-down sales methodology
- Covers clinically and commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and patient share?
- Which events will have the greatest impact on the market’s trajectory?
- What insights do interviewed experts provide on current and emerging treatments?
- Which pipeline products show the most promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for target profiles?
- What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
- and more…
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
Table of contents (TOC)
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)